Solara Active Pharma Sciences Share Price

NSE
SOLARA •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Solara Active Pharma Sciences
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
44.37% Fall from 52W High
-38.6
TTM PE Ratio
Negative PE TTM
-7.8
Price to Book Ratio
Below industry Median
1.8
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is negative
-0.4

Solara Active Pharma Sciences Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Solara Active Pharma Sciences Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
300.31 Cr
346.95 Cr
363.49 Cr
299.43 Cr
248.73 Cr

Solara Active Pharma Sciences Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
1294.29 Cr
1466.36 Cr
1288.36 Cr
1645.65 Cr
1349.27 Cr

Solara Active Pharma Sciences Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
8.09 Cr
8.01 Cr
-13.46 Cr
-255.45 Cr
-275.34 Cr

Solara Active Pharma Sciences Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
-566.96 Cr
-22.25 Cr
-58.29 Cr
221.35 Cr
114.52 Cr
Solara Active Pharma Sciences Result Highlights
  • Solara Active Pharma Sciences Ltd reported a 13.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 21.1%.

  • Its expenses for the quarter were down by 13.4% QoQ and 36.4% YoY.

  • The net profit increased 1.0% QoQ and decreased 102.9% YoY.

  • The earnings per share (EPS) of Solara Active Pharma Sciences Ltd stood at 2 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Solara Active Pharma Sciences shareholding Pattern

Promoter
37.2%
Foreign Institutions
14.7%
Mutual Funds
1.3%
Domestic Institutions
3.2%
Public
44.9%
Promoter
37.3%
Foreign Institutions
14.2%
Mutual Funds
1.3%
Domestic Institutions
3.4%
Public
45.1%
Promoter
37.3%
Foreign Institutions
14%
Mutual Funds
1.3%
Domestic Institutions
2.8%
Public
45.9%
Promoter
30.5%
Foreign Institutions
15.8%
Mutual Funds
1.7%
Domestic Institutions
3%
Public
50.7%
Promoter
30.5%
Foreign Institutions
16.6%
Mutual Funds
1.7%
Domestic Institutions
1.8%
Public
51.1%
Promoter
37.2%
Foreign Institutions
17.9%
Mutual Funds
1.8%
Domestic Institutions
1.7%
Public
43.2%

Solara Active Pharma Sciences Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
2
Bearish Moving Averages
14
5Day EMA
483.20
10Day EMA
494.30
12Day EMA
499.50
20Day EMA
521.90
26Day EMA
538.60
50Day EMA
592.50
100Day EMA
636.80
200Day EMA
619.00
5Day SMA
481.20
10Day SMA
495.30
20Day SMA
507.80
30Day SMA
556.60
50Day SMA
608.80
100Day SMA
693.80
150Day SMA
696.40
200Day SMA
645.20
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
131158 Rs
198777 Rs
Week Rs
86001 Rs
140589 Rs
Month Rs
83860 Rs
157899 Rs
Resistance & Support
482.50
Pivot
Resistance
First Resistance
500
Second Resistance
508.90
Third Resistance
526.40
Support
First Support
473.60
Second support
456.10
Third Support
447.20
Relative Strength Index
38
Money Flow Index
48.64
MACD
-39.16
MACD Signal
-40.84
Average True Range
30.42
Average Directional Index
43.45
Rate of Change (21)
-21.06
Rate of Change (125)
-29.70

Solara Active Pharma Sciences Company background

Founded in: 2017
Solara Active Pharma Sciences Limited was incorporated on February 23, 2017 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs). The Company has 6 APIs manufacturing plants located in Ambernath, Mangalore, Mysuru, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,580 kilo litres and two RD Centres in Chennai and Bengaluru. The Company offer rich basket of niche highvalue products for global markets. The Company has developed 80+ commercial APIs predominantly in anthelmintic, antimalarias, antiinfective, neuromuscular insomnia and antipsychotic hyperkalemia segments, among others. It also reinforce entry barriers to competition and build strong intrinsic value through market specific launches. Apart from this, the Solara Active has two research and development units in Bengaluru and Chennai equipped with stateoftheart facilities and a pipeline of 25+ products, at different stages of development. These drugs primarily deal with anthelmintic, antimalarias, beta blockers, muscle relaxants, novel oral anticoagulants, antiinfective and other niche segments.The Companys manufacturing facilities enjoy regulatory approvals from the United States Food and Drug Administration (USFDA) European Directorate for the Quality of Medicines (EDQM) Korea Food Drug Administration (KFDA) South Korea Euro Zone Good Manufacturing Practice (EUGMP) Danish, World Health Organization (WHO) Geneva Medicines and Healthcare products Regulatory Agency (MHRA) Federal Commission for the Protection against Sanitary Risk (Cofepris) Mexico Therapeutic Goods Administration (TGA) Australia Pharmaceuticals and Medical Devices Agency (PMDA) Japan.The Company acquired 100% of the equity shares of Strides Chemicals Private Limited and made it the wholly owned subsidiary of the Company effective from September 1, 2018. During the year 201819, the Companys wholly owned subsidiary Strides Chemicals Private Limited amalgamated with the Company on December 20, 2019 and the merger was given effect in February, 2020. The Companys new Greenfield plant situated at SEZ unit, Plot No.:3B,3C,3D, Part 2 and 2A1, APIIC APSEZ, Atchutapuram Village, Rambilli Mandal, Visakhapatnam 531011, Andhra Pradesh, commenced commercial production in 2021.The Company acquired 487000 additional stake in Sequent Penems Private Limited, subsidiary company and subsequently Sequent Pharma became the wholly owned subsidiary of Company effective from April 27, 2021. In 2024, the Company sold its entire shareholding in Sequent Penems Private Limited to Symbio Generrics India Private Limited and Sequent Penems Private Limited ceased to be asubsidiary of the Company with effect from April 25, 2024..
Read More

Solara Active Pharma Sciences FAQs

Solara Active Pharma Sciences share price is ₹491.1 in NSE and ₹490.15 in BSE as on 20/2/2025 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

Solara Active Pharma Sciences share price in the past 1-year return was 11.56. The Solara Active Pharma Sciences share hit a 1-year low of Rs. 327.22 and a 1-year high of Rs. 882.8.

The market cap of Solara Active Pharma Sciences is Rs. 2052.9 Cr. as of 20/2/2025 12:00:00 AM.

The PE ratios of Solara Active Pharma Sciences is 0 as of 20/2/2025 12:00:00 AM.

The PB ratios of Solara Active Pharma Sciences is 1.62 as of 20/2/2025 12:00:00 AM

The Mutual Fund Shareholding in Solara Active Pharma Sciences was 1.28% at the end of 20/2/2025 12:00:00 AM.

You can easily buy Solara Active Pharma Sciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -